Aruba vs Saint Vincent and the Grenadines: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Aruba
0.2%
in 2024
Saint Vincent and the Grenadines
0.2%
in 2024
Aruba rank
98th
Saint Vincent and the Grenadines rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Aruba
- Saint Vincent and the Grenadines
How they compare
Aruba currently reports 0.2% against 0.2% in Saint Vincent and the Grenadines, a difference of 0.0%.
Across all 10 years both countries report, Saint Vincent and the Grenadines has been ahead every year.
Aruba ranks 98th and Saint Vincent and the Grenadines ranks 98th of 246 countries.
Head to head by decade
| Decade | Aruba | Saint Vincent and the Grenadines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Aruba or Saint Vincent and the Grenadines?
- Aruba, at 0.2% against 0.2% in Saint Vincent and the Grenadines as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Aruba and Saint Vincent and the Grenadines?
- 0.0%, with Aruba ahead.
- How many years of comparable data are there for Aruba and Saint Vincent and the Grenadines?
- 10 years are reported by both, from 2015 to 2024.
- How do Aruba and Saint Vincent and the Grenadines rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Aruba ranks 98th and Saint Vincent and the Grenadines ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.